TradingView
fredtahmasian
22 lis 2017 04:10

Nightstar Therapeutics 

NASDAQ:NITE

Opis

⋅
11/20/2017
800M market cap. 23 employees. UK.
69M in cash. Burning 10M/yr
a gene therapy for the treatment of CHM. We expect to begin Phase 3 clinical development of NSR-REP1 in the first half of 2018. Phase II data due?
Beyond Technical Analysis
Komentarze
fredtahmasian
⋅
Study.
Więcej